Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Cprit Finance And Governance topic
No spam. Unsubscribe anytime.
CPRIT CEO highlights annual report and staffing; CFO reports $11 million in revenue sharing, Welareg royalties rising
Summary
CPRIT Chief Executive Officer Kristin Doyle presented the annual report and legislative and staffing updates while Chief Financial Officer Grant Weaver reported roughly $11 million in revenue sharing since inception, about $4.5 million from royalties on the drug Welareg, and recent bond issuance activity.
Kristin Doyle, chief executive officer of the Cancer Prevention and Research Institute of Texas, used her CEO report to highlight CPRIT’s 2024 annual report, staffing levels, and recent legislative activity; Chief Financial Officer Grant Weaver summarized revenue sharing, royalties and bond issuances.
Why it matters: The CEO and CFO updates provide oversight committee members and the public with the agency’s fiscal status, staffing constraints, legislative engagement and measures of program impact — information that shapes the agency’s budget requests and operational planning.
CEO update: Doyle said the agency timed the annual CEO report to follow publication of CPRIT’s 2024 Texas cancer plan and highlighted the agency’s grant portfolio and program impact. She told the committee that CPRIT has made nearly 2,100 grant awards since inception and emphasized the agency’s work on clinical trials and prevention programs showcased in the annual report. Doyle reported that CPRIT has 53 full‑time employees, including nine long‑term employees, and said the agency is currently above its FTE cap. She said draft appropriations (House Bill 1 and Senate Bill 1) include a request for 10 additional FTEs and that CPRIT will present its budget request to the House Appropriations Committee on Feb. 24; she said a member of the oversight committee will represent the committee at that hearing.
Doyle also noted space constraints if additional staff are approved and said CPRIT uses a robust remote‑work policy to manage capacity.
CFO update: Grant Weaver reported that CPRIT has earned about $11 million in revenue sharing since inception, and that approximately $4.5 million of that total is attributable to royalties from sales of Welareg. Weaver cited recent public statements by Merrick (the product’s commercial partner) showing year‑over‑year sales growth for Welareg of roughly 33 percent, and he correlated that increase with higher royalty payments to CPRIT. Weaver said royalty payments included roughly $205,000 in October and about $240,000 in January, compared with about $108,000 in a January from the prior year. He described the revenue trend as encouraging for future collections but noted that receipts depend on commercial performance.
Weaver also summarized borrowing activity, saying the agency issued nearly $70 million in December (to support prevention and research awards for prior fiscal years), bringing total FY2025 issuances to about $155.5 million and total bond issuances since the agency’s inception to roughly $3.3 billion.
Other items: Doyle walked through the agency’s work on the 2024 Texas cancer plan, the annual report’s theme on clinical trials, and the agency’s staffing and legislative outreach. She thanked oversight committee members for support in legislative testimony.
Provenance: The CEO and CFO summaries are drawn from the CEO’s report and the CFO’s financial presentation to the oversight committee as recorded in the meeting transcript.
Ending: Doyle and Weaver said staff will continue to provide updates on the budget, staffing requests, revenue sharing and program outcomes at future oversight committee meetings.
